| Budget Amount *help |
¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000)
Fiscal Year 2013: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2012: ¥6,370,000 (Direct Cost: ¥4,900,000、Indirect Cost: ¥1,470,000)
Fiscal Year 2011: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Research Abstract |
In salivary gland cancers, RB1CC1 was demonstrated to be a useful prognostic predictor. In head and neck carcinomas, QL1 & WRN DNA helicase were therapeutic targetting molecules, and the siRNA silencing could result specifically cell death in the cancers. p62/SQSTM1 was highly expressed in head and neck carcinomas. p62/SQSTM1 could induce GSH, cause a resistance to oxidative stress, be associated with a resisitance to radiation therapy, and finally predict the worse prognosis. In testicular embryonal carcinomas, SOX2-siRNA caused significant inhibition for the tumor growth in vivo, suggesting that it will be a promising therapeutic target in the future.
|
